Investor Relations Captor Therapeutics ®

Selected Financial Data

Consolidated statement of financial position

(PLN, thousand) wykres słupkowy

Available funding secured

(PLN M; as of 31.03.2022) wykres kołowy

Selected financial data for the period of 5 years

  From 1 January to 31 December For the period of 6 months ended 30 June
  2022 2021 2020 2019 2018 2022 2021 2020 2019
Income (Research and development income and Other operating income) 32.004 28.629 21.617 15.968b) 9.909b) 13.766 11.227 12.486b) 7.128b)
Operating profit (loss) -38.364 -31.709 -12.216 -7.855a) -4.130a) -20.850 -12.130 -4.487b) -2.875b)
Net profit (loss) -35.894 -32.572 -12.694 -8.306a) -4.422a) -20.840 -12.801 -4.790b) -3.109b)
Net profit (loss) attributable to the shareholders of the parent company -35.849 -32.572 -12.694 -8.306a) -4.422a) -20.840 -12.801 -4.790b) -3.109b)

Source: INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS, a) audited, b) unaudited

  On December 31 On June 30
  2022 2021 2020 2019 2018 2022 2021 2020
Total Assets 113.000 143.541 25.779 25.298 18.061 121.048 157.126 29.366
Equity 96.322 124.201 -1.004 4.278 3.431 108.180 139.200 1.851

Source: INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS